Oligonucleotide Therapeutics Market Report

Global Oligonucleotide Therapeutics Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 07, 2022
  • PAGES：180
  • REPORT CODE：GMM831661
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Oligonucleotide Therapeutics market report explains the definition, types, applications, major countries, and major players of the Oligonucleotide Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Arrowhead Pharmaceuticals

    • GlaxoSmithKline

    • Ionis Pharmaceuticals

    • miRagen Therapeutics

    • Sarepta Therapeutics

    By Type:

    • Antisense/RNAi oligonucleotides

    • Others

    By End-User:

    • Neurological disorders

    • Cancer

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Oligonucleotide Therapeutics Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Oligonucleotide Therapeutics Outlook to 2028- Original Forecasts

    • 2.2 Oligonucleotide Therapeutics Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Oligonucleotide Therapeutics Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Oligonucleotide Therapeutics Market- Recent Developments

    • 6.1 Oligonucleotide Therapeutics Market News and Developments

    • 6.2 Oligonucleotide Therapeutics Market Deals Landscape

    7 Oligonucleotide Therapeutics Raw Materials and Cost Structure Analysis

    • 7.1 Oligonucleotide Therapeutics Key Raw Materials

    • 7.2 Oligonucleotide Therapeutics Price Trend of Key Raw Materials

    • 7.3 Oligonucleotide Therapeutics Key Suppliers of Raw Materials

    • 7.4 Oligonucleotide Therapeutics Market Concentration Rate of Raw Materials

    • 7.5 Oligonucleotide Therapeutics Cost Structure Analysis

      • 7.5.1 Oligonucleotide Therapeutics Raw Materials Analysis

      • 7.5.2 Oligonucleotide Therapeutics Labor Cost Analysis

      • 7.5.3 Oligonucleotide Therapeutics Manufacturing Expenses Analysis

    8 Global Oligonucleotide Therapeutics Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Oligonucleotide Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Oligonucleotide Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    9 Global Oligonucleotide Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Oligonucleotide Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Antisense/RNAi oligonucleotides Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Oligonucleotide Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Neurological disorders Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Oligonucleotide Therapeutics Market Analysis and Outlook till 2022

    • 10.1 Global Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.2.2 Canada Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.2.3 Mexico Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.2 UK Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.3 Spain Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.4 Belgium Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.5 France Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.6 Italy Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.7 Denmark Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.8 Finland Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.9 Norway Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.10 Sweden Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.11 Poland Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.12 Russia Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.3.13 Turkey Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.2 Japan Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.3 India Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.4 South Korea Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.5 Pakistan Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.6 Bangladesh Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.7 Indonesia Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.8 Thailand Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.9 Singapore Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.10 Malaysia Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.11 Philippines Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.4.12 Vietnam Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.2 Colombia Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.3 Chile Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.4 Argentina Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.5 Venezuela Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.6 Peru Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.7 Puerto Rico Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.5.8 Ecuador Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.6.2 Kuwait Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.6.3 Oman Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.6.4 Qatar Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.7.2 South Africa Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.7.3 Egypt Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.7.4 Algeria Oligonucleotide Therapeutics Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Oligonucleotide Therapeutics Consumption (2017-2022)

      • 10.8.2 New Zealand Oligonucleotide Therapeutics Consumption (2017-2022)

    11 Global Oligonucleotide Therapeutics Competitive Analysis

    • 11.1 Arrowhead Pharmaceuticals

      • 11.1.1 Arrowhead Pharmaceuticals Company Details

      • 11.1.2 Arrowhead Pharmaceuticals Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Arrowhead Pharmaceuticals Oligonucleotide Therapeutics Main Business and Markets Served

      • 11.1.4 Arrowhead Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 GlaxoSmithKline

      • 11.2.1 GlaxoSmithKline Company Details

      • 11.2.2 GlaxoSmithKline Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 GlaxoSmithKline Oligonucleotide Therapeutics Main Business and Markets Served

      • 11.2.4 GlaxoSmithKline Oligonucleotide Therapeutics Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Ionis Pharmaceuticals

      • 11.3.1 Ionis Pharmaceuticals Company Details

      • 11.3.2 Ionis Pharmaceuticals Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Main Business and Markets Served

      • 11.3.4 Ionis Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 miRagen Therapeutics

      • 11.4.1 miRagen Therapeutics Company Details

      • 11.4.2 miRagen Therapeutics Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 miRagen Therapeutics Oligonucleotide Therapeutics Main Business and Markets Served

      • 11.4.4 miRagen Therapeutics Oligonucleotide Therapeutics Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Sarepta Therapeutics

      • 11.5.1 Sarepta Therapeutics Company Details

      • 11.5.2 Sarepta Therapeutics Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Sarepta Therapeutics Oligonucleotide Therapeutics Main Business and Markets Served

      • 11.5.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Oligonucleotide Therapeutics Market Outlook by Types and Applications to 2028

    • 12.1 Global Oligonucleotide Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Antisense/RNAi oligonucleotides Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Oligonucleotide Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Neurological disorders Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Oligonucleotide Therapeutics Market Analysis and Outlook to 2028

    • 13.1 Global Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.2.2 Canada Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.2 UK Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.3 Spain Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.5 France Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.6 Italy Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.8 Finland Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.9 Norway Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.11 Poland Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.12 Russia Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.2 Japan Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.3 India Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.3 Chile Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.6 Peru Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.6.3 Oman Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Oligonucleotide Therapeutics Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Oligonucleotide Therapeutics

    • Figure of Oligonucleotide Therapeutics Picture

    • Table Global Oligonucleotide Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Oligonucleotide Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Antisense/RNAi oligonucleotides Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Neurological disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Table North America Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure United States Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Canada Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Mexico Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure Germany Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure UK Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Spain Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Belgium Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure France Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Italy Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Denmark Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Finland Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Norway Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Sweden Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Poland Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Russia Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Turkey Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table APAC Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure China Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Thailand Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Singapore Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Philippines Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table South America Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure Brazil Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Colombia Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Chile Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Argentina Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Peru Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table GCC Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure Bahrain Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Oman Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Qatar Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Africa Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure Nigeria Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Africa Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Egypt Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Algeria Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Oceania Oligonucleotide Therapeutics Consumption by Country (2017-2022)

    • Figure Australia Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Oligonucleotide Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Arrowhead Pharmaceuticals Company Details

    • Table Arrowhead Pharmaceuticals Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arrowhead Pharmaceuticals Oligonucleotide Therapeutics Main Business and Markets Served

    • Table Arrowhead Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio

    • Table GlaxoSmithKline Company Details

    • Table GlaxoSmithKline Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Oligonucleotide Therapeutics Main Business and Markets Served

    • Table GlaxoSmithKline Oligonucleotide Therapeutics Product Portfolio

    • Table Ionis Pharmaceuticals Company Details

    • Table Ionis Pharmaceuticals Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ionis Pharmaceuticals Oligonucleotide Therapeutics Main Business and Markets Served

    • Table Ionis Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio

    • Table miRagen Therapeutics Company Details

    • Table miRagen Therapeutics Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table miRagen Therapeutics Oligonucleotide Therapeutics Main Business and Markets Served

    • Table miRagen Therapeutics Oligonucleotide Therapeutics Product Portfolio

    • Table Sarepta Therapeutics Company Details

    • Table Sarepta Therapeutics Oligonucleotide Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sarepta Therapeutics Oligonucleotide Therapeutics Main Business and Markets Served

    • Table Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio

    • Figure Global Antisense/RNAi oligonucleotides Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Neurological disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Table North America Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Germany Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure China Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Brazil Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Oligonucleotide Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Australia Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Oligonucleotide Therapeutics Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US